Dr. Edward Ivy

Contributions

FDA Approves Rinvoq for Treatment of Atopic Dermatitis

The U.S. Food and Drug Administration approved Rinvoq (upadacitinib) for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older, the manufacturer announced Friday. The approval is indicated for patients with atopic dermatitis that did not respond to previous treatment and is not well controlled with other medications or when the use...

Dr. Edward Ivy: Improving Access to Care in Sickle Cell Disease

I have lived with sickle cell disease for 48 years. The toll it takes goes far beyond pain – it has impacted me emotionally, economically, and psychosocially. I missed childhood activities because I was too sick or tired. I missed school days and worked harder to catch up on missed assignments. I learned to live...

Exclusive: Canada Told Drugmakers It Would Limit Scope Of Some New Price Rules

TORONTO (Reuters) – The Canadian government has assured the pharmaceutical industry that new features of its plan to cut drug costs would apply only to new medicines, Health Canada said, offering some relief to drugmakers even as other regulations could still lower prices of medicines already on the market. FILE PHOTO: A pharmacist counts pills...

Categories

Stay informed on the latest health disparities research, cultural sensitivity education, and how you can help improve patient outcomes.
This field is for validation purposes and should be left unchanged.